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DELIVERY OF FGF-FAMILY PEPTIDES FOR 
NEOVASCULARIZATION 
Christian Haudenschild, MD
George Washington University Medical Center 
The idea that we might  be able to control  selec- 
tively the format ion o f  b lood vessels keeps attracting 
investigators and investors as well: suppress anglo- 
genesis and thus inhibit  the growth o f  tumors,  or  
provoke it and thus revascularize ischemic tissues, 
and two major killers, cancer and atherosclerosis, are 
el iminated! Whi le this is clearly a naive oversimplifi- 
cat ion,  it is still very  impressive to observe new 
b lood vessels reach toward a corneal pocket  contain- 
ing a piece o f  tumor  or a pellet slowly releasing FGF  
in the best  establ ished in vivo angiogenes is  test. 
Many o f  the other tests cover at least some partial 
aspects o f  angiogenesis  uch as endothe l ia l  cell 
migrat ion, prol i feration, enzymatic activity, or  tube 
formation,  and representative members  o f  the FGF  
family are positive in all o f  these assays. Having FGF  
as a defined pept ide rather than an obscure extract 
and knowing much about  its angiogenic and other 
propert ies,  why has there not  been more sustainable 
progress applying this (and many other  "growth"  
factors) for therapeutic neovascularization in vivo? 
While it is impossible to predict  all interactions o f  
a new therapeutic agent in vivo, some fundamental  
rules observed in tissue culture should not  be over- 
looked. For  example, FGF- I  needs to be applied to 
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the target cells for at least 12 hours to be mito- 
genic, 1yet in vivo it is destroyed within minutes, 
even though heparin and matrix binding may pro- 
vide some protection. Thus, simple injection of FGF 
(or most other angiogenic factors) is unlikely to pro- 
vide sufficient exposure o f  the target cells. Slow 
release carriers, local microinfusions, or resistant 
mutants are strategies to circumvent this known 
shortcoming of growth factor therapy. 
However, when Landau et a12 actually used 
microinfusion of FGF-II through an Alza pump into 
normal pericardium to provoke the formation of 
epicardial vessels, nothing happened until a relative 
ischemia of the myocardium was induced by provo- 
cation of rapid hypertrophy through infusion of 
angiotensin II. Neither totally normal nor totally 
necrotic tissues are likely to respond to a growth fac- 
tor. For a beneficial response, cells have to be alive 
and activated, for example through up-regulation of
receptors, which may be the case at wound edges or 
border zones of infarcts only during a limited time 
period. FGF is part of a complex angiogenic milieu; 
it depends on it, but does not, by itself, create it. 
As soon as an injury scenario is present or is cre- 
ated experimentally, abundant endogenous factors 
come into play, which may obscure the effect and 
the specificity of the initial intervention. When we 
transfected the wall of rat carotid arteries immedi- 
ately after balloon injury with liposomes containing 
a plasmid coding for FGF-I and a reporter gene, we 
achieved both the prolonged presence of the factor 
and the injury scenario. However, the intense 
endothelial cell and fibroblast growth that was occa- 
sionally seen was more likely due to abundant, non- 
transfected macrophages that stained strongly posi- 
tive for FGF-I and outnumbered the transfected 
cells by many orders of magnitude (unpublished). 
Some areas resembled a Kaposi's arcoma more than 
a functional capillary meshwork, suggesting some 
local FGF overstimulation i  addition to simple 
response to injury followed by nonspecific irritation. 
Specificity for vessel formation is not proved for 
any of the currently known angiogenic factors. FGFs 
generally stimulate  variety of mesenchymal cells, 
but sites of very high spontaneous FGF expression i
vivo, such as granulation tissues, are indeed very vas- 
cular. Transfection of porcine arteries with liposomes 
containing FGF-I plasmid showed intimal lesions 
that were more vascular than those of ari!eries trans- 
fected with platelet derived growth factor.3, 4 
However, these vessels were leaky, and the sustained 
vascular growth could be explained by endogenous 
factors contained in the resulting hemorrhages. 
Thus, the local application of FGF may initiate an 
endogenous response that may prolong the predom- 
inantly vascular phase of wound healing, but many 
other factors, nonspecific irritants, local immune 
responses, physical applications such as heat, or sim- 
ple "refreshing" of the wound edge by repeated 
injury can have essentially the same effects. Whether 
such vessels remain open and functional beyond the 
scarring stage remains to be determined. With more 
modest expectations, some time may be gained to 
allow powerful endogenous collateralization mecha- 
nisms to become ffective. 
Despite their names, some "growth" factors may 
also support mere survival, adhesion, migration, and 
other functions of vascular cells. For example, FGF 
incorporated in fibrin for slow release was used sim- 
ply to retain endothelial cells seeded onto balloon 
injured arteries. 5 With the use of FGF-II deficient 
mice, it was also shown that this factor contributes to
the control of vascular tone, but is not essential for 
the development of intimal hyperplasia n response 
to balloon injury. 6 
Thus the potential of therapeutic applications of 
FGF and related peptides is not yet fully explored. 
Planning their practical applications, the increasingly 
known properties of these agents hould be better 
factored in, the activity and sites of action must be 
better controlled, the magnitude of secondary 
effects in vivo need to be more appreciated, and the 
fact that they are neither exclusively vascular nor all 
together growth promoting has to be considered. 
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